Abbott India Limited (ABBOTINDIA) Fair Value & Analysis

Healthcare · IN · Market cap ₹577B

A strong business, but screening 51% overvalued on our models.

What matters now

• A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
• The price sits above even our optimistic bull case (₹18,845). The favourable scenario is already priced in.
• A fairly wide model range (₹10,419 to ₹18,845) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.

How to read this chart

60‑month range ₹6,630 – ₹35,670 · fair‑value band ₹10,419 – ₹18,845 · the ₹27,835 price screens above the ₹13,565 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Abbott India Limited (ABBOTINDIA) currently trades at ₹27,835, while our model-based Fair Value estimate is ₹13,565, implying the stock looks roughly 51.3% overvalued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Abbott India Limited generated revenue of ₹69.3B at a net margin of 22.4%. Revenue grew 6.5% year over year. It earns a return on equity of 34.5%. The balance sheet holds a net cash position of ₹20.8B. Fundamentals as of Jul 13, 2026

Our scenario range runs from ₹10,419 (bear case) to ₹18,845 (bull case); at ₹27,835, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -51%, ABBOTINDIA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (₹17,649) versus Asset-Based (₹1,505). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management.

Full company description

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Abbott India Limited reported revenue of ₹69.3B in FY2026 versus ₹49.1B in FY2022, a compound +9.0%/yr. Reported net income was ₹15.5B in FY2026, compounding +18.1%/yr from FY2022.

ABBOTINDIA screens 51% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.